NASDAQ:BCAB BioAtla (BCAB) Stock Price, News & Analysis $1.31 +0.05 (+3.97%) As of 11:23 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About BioAtla Stock (NASDAQ:BCAB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BioAtla alerts:Sign Up Key Stats Today's Range$1.31▼$1.3150-Day Range$1.08▼$3.5352-Week Range$1.07▼$71.50Volume503 shsAverage Volume54,747 shsMarket Capitalization$2.18 millionP/E RatioN/ADividend YieldN/APrice Target$200.00Consensus RatingHold Company Overview BioAtla, Inc. is a biotechnology company focused on developing antibody-based therapeutics for cancer and other serious diseases. The company’s research has centered on its Conditionally Active Biologics (CAB) technology, which is designed to create antibodies that are preferentially activated in the tumor microenvironment while remaining less active in healthy tissues. BioAtla’s oncology pipeline has included programs directed at targets such as ROR2 and CTLA-4. Its lead candidates have included ozuriftamab (BA3021), an antibody targeting ROR2, and evalstotug (BA3071), an investigational CTLA-4-directed antibody. These programs have been evaluated in clinical studies involving patients with advanced solid tumors, either as standalone treatments or in combination with other cancer therapies. Founded in 2007 and headquartered in San Diego, California, BioAtla conducted its discovery and clinical-development activities primarily in the United States, with clinical research involving international study sites. The company has undergone strategic changes as it evaluated its development programs and corporate alternatives, and publicly available information about its current operations and leadership may be limited.AI Generated. May Contain Errors. Read More BioAtla Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks25th Percentile Overall ScoreBCAB MarketRank™: BioAtla scored higher than 25% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingBioAtla has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialBioAtla has a consensus price target of $200.00, representing about 15,167.2% upside from its current price of $1.31.Amount of Analyst CoverageBioAtla has only been the subject of 1 research reports in the past 90 days.Read more about BioAtla's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of BioAtla is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioAtla is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about BioAtla's valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for BCAB. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioAtla does not currently pay a dividend.Dividend GrowthBioAtla does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search Interest5 people have searched for BCAB on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BioAtla insiders have not sold or bought any company stock.Percentage Held by Insiders9.34% of the stock of BioAtla is held by insiders.Percentage Held by Institutions77.23% of the stock of BioAtla is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BioAtla's insider trading history. Receive BCAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioAtla and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BCAB Stock News HeadlinesBioAtla Announces $40 Million Oncology SPV Investment DealMay 29, 2026 | theglobeandmail.comBioAtla Announces Share ConsolidationMarch 31, 2026 | globenewswire.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.October 5 at 1:00 AM | Porter & Company (Ad)BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business HighlightsMarch 31, 2026 | globenewswire.comBioAtla, Inc. Initiates Strategic Review Process and Workforce Restructuring to Enhance Shareholder ValueMarch 2, 2026 | quiverquant.comQBioAtla Announces Formal Process to Evaluate Strategic Options to Monetize AssetsMarch 2, 2026 | globenewswire.comBioAtla Faces Nasdaq Trading Suspension and Potential DelistingFebruary 6, 2026 | tipranks.comBioAtla Inc.January 21, 2026 | barrons.comSee More Headlines BCAB Stock Analysis - Frequently Asked Questions How have BCAB shares performed this year? BioAtla's stock was trading at $28.3850 at the start of the year. Since then, BCAB shares have decreased by 95.4% and is now trading at $1.31. How were BioAtla's earnings last quarter? BioAtla, Inc. (NASDAQ:BCAB) issued its quarterly earnings data on Thursday, August, 13th. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of ($8.50) by $8.64. The company earned $6.50 million during the quarter, compared to analysts' expectations of $6.50 million. When did BioAtla's stock split? Shares of BioAtla reverse split before market open on Monday, April 6th 2026.A 1-50 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Sunday, April 5th 2026. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. When did BioAtla IPO? BioAtla (BCAB) raised $168 million in an initial public offering (IPO) on Wednesday, December 16th 2020. The company issued 10,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies, Credit Suisse and BTIG acted as the underwriters for the IPO. How do I buy shares of BioAtla? Shares of BCAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioAtla own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioAtla investors own include NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Netflix (NFLX) and Visa (V). Company Calendar Last Earnings8/13/2026Today10/05/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (8m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 BCAB's financial health is in the Red zone, according to TradeSmith. BCAB has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BCAB CIK1826892 Webwww.bioatla.com Phone858-558-0708FaxN/AEmployees60Year Founded2007Price Target and Rating Average Price Target for BioAtla$200.00 High Price Target$200.00 Low Price Target$200.00 Potential Upside/Downside+15,167.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($25.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$59.61 million Net MarginsN/A Pretax Margin-370.05% Return on EquityN/A Return on Assets-289.67% Debt Debt-to-Equity RatioN/A Current Ratio0.20 Quick Ratio0.20 Sales & Book Value Annual Sales$8.50 million Price / Sales0.26 Cash FlowN/A Price / Cash FlowN/A Book Value($28.51) per share Price / Book-0.05Miscellaneous Outstanding Shares1,666,000Free Float1,510,000Market Cap$2.18 million OptionableOptionable Beta0.64 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:BCAB) was last updated on 10/5/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioAtla, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioAtla With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BCAB Stock Alerts